{
  "ticker": "JNJ",
  "target_date": "2025-07-08",
  "actual_date": "2025-07-08",
  "collected_at": "2025-12-08T11:59:11.113312",
  "price": {
    "open": 152.39,
    "high": 154.64,
    "low": 152.12,
    "close": 153.67906188964844,
    "volume": 6438200,
    "change_1d_pct": 0.33,
    "change_7d_pct": 2.49,
    "change_30d_pct": 2.96
  },
  "technicals": {
    "rsi_14": 52.01,
    "sma_20": 151.93,
    "sma_50": 151.19,
    "macd": 0.551,
    "macd_signal": 0.242,
    "macd_histogram": 0.308,
    "bb_upper": 156.34,
    "bb_lower": 147.52,
    "price_vs_sma20_pct": 1.15,
    "price_vs_sma50_pct": 1.65,
    "volume_ratio": 0.81
  },
  "fundamentals": {
    "market_cap": 489412132864,
    "pe_ratio": 19.607626,
    "forward_pe": 19.163677,
    "price_to_book": 6.1655083,
    "price_to_sales": 5.3110957,
    "profit_margin": 27.26,
    "operating_margin": 30.2,
    "roe": 33.62,
    "roa": 8.26,
    "revenue_growth": 6.8,
    "earnings_growth": 91.0,
    "debt_to_equity": 57.766,
    "current_ratio": 1.074,
    "quick_ratio": 0.711,
    "dividend_yield": 258.0,
    "fifty_two_week_high": 207.81,
    "fifty_two_week_low": 140.68,
    "fifty_day_avg": 193.4922,
    "two_hundred_day_avg": 170.2741,
    "analyst_target": 203.41833,
    "analyst_recommendation": "buy",
    "num_analysts": 24,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -2.25,
    "pct_from_52w_low": 44.4
  },
  "macro": {
    "spy": {
      "price": 618.62,
      "change_1d_pct": -0.05,
      "change_7d_pct": 0.88
    },
    "vix": {
      "level": 16.81,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.41
    },
    "dollar_index": {
      "level": 97.51
    },
    "gold": {
      "price": 3307.0
    },
    "regime": "BULL_NORMAL"
  },
  "news": [
    {
      "headline": "Johnson & Johnson (NYSE:JNJ) Submits sNDA For Schizophrenia Drug CAPLYTA\u00ae To FDA",
      "source": "Yahoo",
      "datetime": 1751995618,
      "summary": "Johnson & Johnson (NYSE:JNJ) submitted a supplemental New Drug Application for CAPLYTA\u00ae, aiming to prevent schizophrenia relapse, marking a significant step in expanding its mental health portfolio. Over the last quarter, Johnson & Johnson's stock price increased by 4%. This movement aligns with the",
      "url": "https://finnhub.io/api/news?id=0dda058c5eb97ab0f86a5485aabe0905835e1f8076da4acf8c39439e820ce272"
    },
    {
      "headline": "Trump says pharmaceutical tariffs could reach 200%",
      "source": "Finnhub",
      "datetime": 1751994912,
      "summary": "U.S. President DonaldTrump on Tuesday said he plans to announce tariffs on importedpharmaceuticals which could reach 200% but he would givedrugmakers about one year to get their act together. ...",
      "url": "https://finnhub.io/api/news?id=ad58440456c926559c68bd2e6b6e91ab8c66b954068a94580d45ed2a4b2923e8"
    },
    {
      "headline": "How Will Skyrizi and Rinvoq Sales Aid AbbVie's Upcoming Q2 Results?",
      "source": "Yahoo",
      "datetime": 1751977620,
      "summary": "ABBV leans on Skyrizi and Rinvoq sales strength to offset Humira's decline ahead of its Q2 earnings report.",
      "url": "https://finnhub.io/api/news?id=a18c12cd77ddee6772eeda08f133bcb8c233bd69bdcc839a042f8df8b92a629b"
    },
    {
      "headline": "Supplemental new drug application submitted to U.S. FDA for CAPLYTA\u00ae (lumateperone) with data demonstrating significant schizophrenia relapse prevention compared to placebo",
      "source": "Yahoo",
      "datetime": 1751976000,
      "summary": "Johnson & Johnson (NYSE:JNJ) announced today the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) based upon long-term data evaluating the safety and efficacy of CAPLYTA\u00ae (lumateperone) for the prevention of relapse in schizophrenia. CAPLYTA\u00ae is",
      "url": "https://finnhub.io/api/news?id=5243b80de315ea0759dfc163675e7ded82616c6cbf94d4b972bc4ad522cf5868"
    },
    {
      "headline": "IP Due Diligence: The Make-Or-Break Factor In Modern M&A",
      "source": "Finnhub",
      "datetime": 1751969471,
      "summary": "As innovation cycles accelerate and technology convergence increases, intellectual property has become a powerful driver of major corporate acquisitions. For example, when Johnson & Johnson acquired...",
      "url": "https://finnhub.io/api/news?id=861e15b48b2fb4806d01b6cbbe80ef418e57cbbb3a1b18e5a840834d8db75487"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-06-12",
      "description": "xslF345X05/wk-form4_1749760336.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000156/xslF345X05/wk-form4_1749760336.xml"
    },
    {
      "form": "4",
      "date": "2025-06-12",
      "description": "xslF345X05/wk-form4_1749760229.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000154/xslF345X05/wk-form4_1749760229.xml"
    },
    {
      "form": "8-K",
      "date": "2025-06-10",
      "description": "jnj-20250610.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000152/jnj-20250610.htm"
    },
    {
      "form": "13F-HR",
      "date": "2025-05-07",
      "description": "xslForm13F_X02/primary_doc.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000090445425000238/xslForm13F_X02/primary_doc.xml"
    },
    {
      "form": "4",
      "date": "2025-05-05",
      "description": "xslF345X05/wk-form4_1746479407.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000143/xslF345X05/wk-form4_1746479407.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}